Literature DB >> 1412612

Determination of plicamycin in plasma by radioimmunoassay.

K Fang1, C A Koller, N Brown, W Covington, J R Lin, D H Ho.   

Abstract

This article describes a method for the determination of plicamycin in plasma by radioimmunoassay. The anti-plicamycin antibody was produced against a plicamycin-bovine serum albumin conjugate prepared by using diazotized p-aminobenzoic acid as a cross-linker. The radiolabeled ligand, 125I-plicamycin, was prepared by the chloramine-T method. The linear plicamycin concentration range was 7-400 ng/ml. The coefficients of variation for intra- and interday variabilities were 7.5 and 15%, respectively. No interference was observed from either the structurally related chromomycin A or concomitantly used drugs hydroxyurea or allopurinol. With this method of testing, plicamycin levels in plasma could be determined in patients receiving small (0.85-1.0 mg/m2) therapeutic plicamycin doses. Preliminary pharmacokinetic data in humans indicate that the plasma drug disappearance curve was biphasic with a mean elimination half-life of 10.6 +/- 1.7 h, total clearance rate of 11.1 +/- 0.4 ml/min/m2, and area under the plasma drug concentration-time curve of 1,289-1,546 ng-h/ml. This assay method is clinically useful for pharmacokinetic studies of plicamycin and may be helpful in the design of rational therapeutic drug trials.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1412612     DOI: 10.1097/00007691-199206000-00013

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

1.  Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application.

Authors:  Jeffrey Roth; Cody J Peer; Brigitte Widemann; Diane E Cole; Rachel Ershler; Lee Helman; David Schrump; William D Figg
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-09-06       Impact factor: 3.205

2.  The Sp1 transcription factor is essential for the expression of gliostatin/thymidine phosphorylase in rheumatoid fibroblast-like synoviocytes.

Authors:  Kenji Ikuta; Yuko Waguri-Nagaya; Kae Kikuchi; Takaya Yamagami; Masahiro Nozaki; Mineyoshi Aoyama; Kiyofumi Asai; Takanobu Otsuka
Journal:  Arthritis Res Ther       Date:  2012-04-25       Impact factor: 5.156

3.  Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia.

Authors:  Monica M Kangussu-Marcolino; Gretchen M Ehrenkaufer; Emily Chen; Anjan Debnath; Upinder Singh
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-10-22       Impact factor: 4.284

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.